16:36 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Banyan reports 97.6% sensitivity for TBI diagnostic

Banyan Biomarkers Inc. (Alachua, Fl.) said data from the ALERT-TBI study showed that its blood-based diagnostic Banyan BTI had 97.6% sensitivity and a 99.6% negative predictive value (NPV) for detecting intracranial injury to rule out...
19:38 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

FDA approves Banyan's brain trauma blood test

FDA approved the Banyan Brain Trauma Indicator (BTI) from Banyan Biomarkers Inc. (Alachua, Fla.) as an in vitro diagnostic blood test to aid in the evaluation of adults with suspected mild traumatic brain injury (TBI)....
18:02 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse and monkey studies suggest inhibiting all forms of tau, not only hyperphosphorylated tau, could help treat AD and other tauopathies. In monkeys, an antisense oligonucleotide (ASO) against monkey tau decreased...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Muscarinic acetylcholine receptor M1 (CHRM1; HM1); glial fibrillary acidic protein (GFAP)

Neurology INDICATION: Leukodystrophy Patient sample, fly and mouse studies suggest inhibiting CHRM1 could help treat Alexander disease, which is caused by GFAP mutations that result in impaired glial cell function. In postmortem patient brain tissue, CHRM1 levels...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Glioblastoma multiforme (GBM) circulating tumor cells (CTCs) to diagnose peripheral metastases Studies in patient samples suggest detecting CTCs could help...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Company News

NsGene, StemCells deal

StemCells acquired from NsGene a patent family, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. The patents claim cell cultures of glial fibrillary acidic protein (GFAP) and intermediate filament marker...
07:00 , Aug 16, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); glial fibrillary acidic protein (GFAP) Mouse studies suggest increasing...
08:00 , Jan 27, 2003 |  BC Week In Review  |  Company News

Syn x other research news

Researchers published in Nature Medicine that immunotherapy with glial fibrillary acidic protein (GFAP) and S100beta proteins was protective in mouse models of Type I diabetes. Thus, the researchers suggested that autoimmune targeting of the pancreatic...
08:00 , Nov 13, 2000 |  BC Week In Review  |  Company News

AlphaGene other research news

AlphaGene said that it has identified 2 genes expressed at abnormally high levels in AD brain tissue compared to normal tissue. In protein interaction studies, the company said one of the genes, which may be...